Phillips Edison & Co Inc (PECO) Q4 2024 Earnings Call Highlights: Strong Growth Amidst ...
Core FFO per Share Growth: Nearly 4% in 2024, potentially 6% if adjusted for interest rates.
Acquisitions: Closed nearly $100 million in Q4; targeting $350 million to $450 million in 2025.
Comparable New Rent Spreads: 30.2% in Q4.
Comparable Renewal Rent Spreads: 20.8% in Q4.
Portfolio Occupancy: 98% leased at the end of Q4.
NAREIT FFO: $83.8 million or $0.61 per diluted share in Q4, 8.9% YoY growth.
Core FFO: $85.8 million or $0.62 per diluted share in Q4, 6.9% YoY growth.
Same-Center NOI Growth: 6.5% in Q4.
Liquidity: Approximately $948 million as of December 31, 2024.
Net Debt to Adjusted EBITDAR: 5 times.
2025 Guidance for NAREIT FFO: $2.47 to $2.54 per share, 5.7% increase over 2024 at midpoint.
2025 Guidance for Core FFO: $2.52 to $2.59 per share, 5.1% increase over 2024 at midpoint.
2025 Same-Center NOI Growth Guidance: 3% to 3.5%.
Warning! GuruFocus has detected 8 Warning Signs with PECO.
Release Date: February 07, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Phillips Edison & Co Inc (NASDAQ:PECO) delivered solid core FFO per share growth of nearly 4% in 2024, despite significant interest expense headwinds.
Retailer demand across PECO's portfolio remains strong, evidenced by high occupancy rates and strong rent spreads.
PECO exceeded the high end of its original guidance for acquisitions in 2024, closing nearly $100 million in acquisitions in the fourth quarter.
The company has a high-quality portfolio capable of delivering strong cash flow growth, with approximately 70% of ABR coming from necessity-based goods and services.
PECO's low leverage provides financial capacity to meet growth targets, with diverse sources of capital including additional debt issuance, dispositions, and equity.
Significant interest expense headwinds impacted core FFO per share growth, which would have been higher without these expenses.
Several retailers, including Party City and Big Lots, filed for bankruptcy, although PECO has low exposure to these retailers.
The transaction market is competitive, with more buyers putting pressure on pricing, which could impact acquisition opportunities.
PECO's strategy of taking back weaker stores to improve merchandising may temporarily put downward pressure on occupancy and retention rates.
The company faces potential headwinds from tariffs and higher labor costs, which could impact retailer operations and consumer spending.
Q: How does the current tenant demand and acquisition pipeline compare to last year? A: Jeffrey Edison, CEO, stated that they feel better about the current year compared to last year due to a larger pipeline of projects under contract and controlled. They had a strong fourth quarter with nearly $100 million in acquisitions, and they have higher goals for acquisitions this year. The market continues to show a strong pipeline of products, although there is more competition, which is putting pressure on pricing.
Q: How is PECO balancing high occupancy with tenant retention? A: Jeffrey Edison, CEO, explained that PECO is taking a more aggressive approach to merchandising by taking back weaker stores when leases are up, which may temporarily affect occupancy and retention. However, this strategy is expected to improve long-term growth by enhancing the merchandising mix and property value.
Q: What role do dispositions play in funding acquisitions, and how does PECO balance capital recycling with new equity or debt? A: Jeffrey Edison, CEO, mentioned that the market will determine the best source of capital, whether through debt, equity, or dispositions. They have already announced one disposition this year and will continue to use this strategy selectively when they can achieve better returns on acquisitions than on sales.
Q: Can you provide more details on the joint venture partnerships and their role in acquisitions? A: Jeffrey Edison, CEO, noted that joint ventures represent about 10% of their acquisition target for the year. These partnerships, such as those with Cohen & Steers and Northwestern Mutual, allow PECO to pursue unique opportunities that may not fit their balance sheet but still offer solid investment potential.
Q: How is PECO addressing potential tenant credit concerns and bad debt? A: John Caulfield, CFO, stated that PECO's bad debt experience in 2024 was around 75 basis points, and they have set a wider guidance range for 2025 to account for potential variability. They feel confident in the strength of their tenants and have low exposure to known bankruptcies like Party City and Big Lots.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Tom Lee Dismisses Worries Over Tumbling TSLA Stock Amid Elon Musk-Trump Feud: 'Tesla Still Holds All Of Its Advantages, So We Aren't Too Concerned'
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Tesla Inc. (NASDAQ:TSLA) saw a sharp decline last week as the tensions between Elon Musk and President Donald Trump flared up on social media, however, this expert predicts no change in its long-term view despite the fall. What Happened: After Trump and Musk's public spat on Thursday, the automaker erased over $152 billion in market capitalization; however, Tom Lee, the CIO at Fundstrat Capital, remains positive on the stock. In a video reshared on X, Lee said, the decline that we have seen recently is just coming back to support. 'I don't think the long-term picture has changed much for Tesla,' he said. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Furthermore, he highlighted Tesla's leadership and competitive strength in electric vehicle design and manufacturing, an affordable robotaxi product launching soon, Optimus robots with movement dexterity, and its foray into drones. 'Will all that Tesla still holds all of its advantages, so we aren't too concerned about the decline,' Lee Wedbush analyst Dan Ives also reiterated Lee's views, saying that 'Trump/Musk going from BFFs to frenemies does not change our bullish view of the autonomous path looking forward.' He said that Wedbush still expects Trump to green light the regulatory federal framework for autonomous vehicles regardless of the feud. Why It Matters: Tensions rose between Musk and Trump when he called the 'Big Beautiful Bill' a "disgusting abomination" earlier this week, and both were seen allaying accusations against each other over the disagreement on the bill Thursday. However, the stock rose 3.67% on Friday after a signal that both parties could be headed for a truce. Lee's Fundstrat Granny Shots US Large Cap ETF (NYSE:GRNY), which holds about 38 stocks, includes Tesla with 2.27% of weight. Apart from this, the exchange-traded fund's top holdings include Robinhood Markets Inc. (NASDAQ:HOOD) with a weight of 3.06%, General Electric Co. (NYSE:GE) at 2.96%, GE Vernova Inc. (NYSE:GEV) at 2.83% and Nvidia Corp. (NASDAQ:NVDA) weighting 2.79%. The GRNY ETF has gained 7.28% on a year-to-date basis, and it has been up 4.30% since its inception in November last year. Despite Tesla's decline, the ETF rose 3.04% over the last week. Shares of Tesla slumped 14.11% in the last week, and they were down by 22.18% in 2025. However, over the last year, the stock has risen by 69.83%. Read Next: In terms of getting money back, these bank accounts put traditional checking and savings accounts to shame. Maximize saving for your retirement and cut down taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. Photo courtesy: Tada Images / This article Tom Lee Dismisses Worries Over Tumbling TSLA Stock Amid Elon Musk-Trump Feud: 'Tesla Still Holds All Of Its Advantages, So We Aren't Too Concerned' originally appeared on
Yahoo
28 minutes ago
- Yahoo
Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
ROCKVILLE, Md. and SUZHOU, China, June 09, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that 13 studies of its core assets - including the novel drug olverembatinib (HQP1351), the investigational Bcl-2 inhibitor lisaftoclax (APG-2575), and the investigational EED inhibitor APG-5918 – will be featured in an oral presentation, multiple poster presentations and multiple online publications at the 2025 European Hematology Association (EHA) Annual Congress taking place in Milan, Italy, from June 12-15, 2025. The EHA Annual Congress is the largest gathering of the hematology community in Europe. Attracting more than 10,000 attendees from more than 100 countries every year, the congress showcases cutting-edge research and ground-breaking clinical results in the field of hematology. Oral PresentationIntegrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy Abstract#: S162 Session: Biology of CML treatment response and resistance Date and Time: Saturday, 14 June, 17:30-17:45 CEST / Saturday, 14 June, 23:30-23:45 Beijing Time Principal Authors: Prof. Qian Jiang, Peking University People's Hospital; Dr. Xiaoshuai Zhang, Peking University People's Hospital Poster PresentationsFrontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study Abstract#: PF384 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time Principal Author: Prof. Xiaowen Tang, The First Affiliated Hospital of Soochow University; Xin Zhang, The First Affiliated Hospital of Soochow University A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Abstract#: PF390 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Suning Chen, The First Affiliated Hospital of Soochow University; Wenzhi Cai, The First Affiliated Hospital of Soochow University Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia Abstract#: PS1367 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Hongsheng Zhou, Nanfang Hospital, Southern Medical University; Xiuli Xu, Nanfang Hospital, Southern Medical University Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial Abstract#: PS1372 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Jie Jin, The First Affiliated Hospital, Zhejiang University School of Medicine; Dr. Gaixiang Xu, The First Affiliated Hospital, Zhejiang University School of Medicine Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study Abstract#: PS1387 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Author: Erlie Jiang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Xiaoyu Zhang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models Abstract#: PS1993 Session: Lymphoma biology & translational research Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Principal Author: Dr. Eric Liang, Ascentage Pharma Group Inc. Online PublicationsAlternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis Abstract: PB2384 Principal Author: Prof. Zi-Yuan Nie, The Second Hospital of Hebei Medical University Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive/Negative B-Cell Acute Lymphoblastic Leukemia Abstract#: PB2363 Principal Author: Yinqiang Zhang, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Abstract#: PB2360 Principal Author: Xinwen Jiang, The Second Hospital of Hebei Medical University Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study Abstract#: PB2701 Principal Author: Mengyao Yuan, Peking University People's Hospital A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study Abstract#: PB2714 Principal Author: Tian Dong, West China Hospital of Sichuan University Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL) Abstract#: PB2341 Principal Author: Bo Peng, Ascentage Pharma (Suzhou) Co., Ltd. About Ascentage PharmaAscentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph+ ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML, and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma +86 512 85557777 Stephanie Carrington ICR Healthcare +1 (646) 277-1282 Media Relations: Sean Leous ICR Healthcare +1 (646) 866-4012
Los Angeles Times
40 minutes ago
- Los Angeles Times
US stocks drift and Chinese markets rise as trade talks start between the world's largest economies
NEW YORK — U.S. stocks drifted through a quiet Monday as the world's two largest economies began talks on trade that could help avoid a recession. The Standard & Poor's 500 edged up by 0.1% and is within 2.3% of its record, which was set in February. The Dow Jones Industrial Average slipped by 1 point, which is well below 0.1%, and the Nasdaq composite added 0.3%. Officials from the United States and China met in London to talk about a range of different disputes that are separating them. The hope is that they can eventually reach a deal that will lower each's punishing level of tariffs against the other, which are currently on pause, so that the flow of everything from tiny tech gadgets to enormous machinery can continue. Hopes that President Trump will lower his tariffs after reaching such trade deals with countries around the world have been among the main reasons the S&P 500 has rallied so furiously since dropping roughly 20% from its record two months ago. It's back above where it was when Trump shocked financial markets in April with his wide-ranging tariff announcement on what he called 'Liberation Day.' This may be the shortest sell-off following a shock of heightened volatility on record, according to Parag Thatte, Binky Chadha and other strategists at Deutsche Bank. Typically, stocks take around two months to bottom following a spike in volatility and then another four to five months to recover their losses. This time around, stocks have basically made a round trip in less than two months. But nothing is assured, of course, and that helped keep trading relatively quiet on Wall Street Monday. Some of the market's biggest moves came from the announcement of big buyout deals. Qualcomm rallied 4.1% after saying it agreed to buy Alphawave Semi in a deal valued at $2.4 billion. IonQ, meanwhile, rose 2.7% after the quantum computing and networking company said it agreed to purchase Oxford Ionics for nearly $1.08 billion. On the losing side of Wall Street was Warner Bros. Discovery, which flipped from a big early gain to a loss of 3% after saying it would split into two companies. One will get Warner Bros. Television, HBO Max and other studio brands, while the other will hold onto CNN, TNT Sports and other entertainment, sports and news television brands around the world, along with some digital products. Tesla recovered some of its sharp, recent drop. The electric vehicle company tumbled last week as Elon Musk's relationship with Trump broke apart, and it rose 4.6% Monday after flipping between gains and losses earlier in the day. The frayed relationship could end up damaging Musk's other companies that get contracts from the U.S. government, such as SpaceX. Rocket Lab, a space company that could pick up business at SpaceX's expense, rose 2.5%. All told, the S&P 500 rose 5.52 points to 6,005.88. The Dow Jones Industrial Average slipped 1.11 to 42,761.76, and the Nasdaq composite rose 61.28 to 19,591.24. In stock markets abroad, indexes were modestly lower in Europe after rising across much of Asia. Chinese markets climbed even though the government reported that exports slowed in May, growing 4.8% from a year earlier after jumping more than 8% in April. China also reported that consumer prices fell 0.1% in May from a year earlier, marking the fourth consecutive month of deflation. Stocks rallied 1.6% in Hong Kong and rose 0.4% in Shanghai. In the bond market, the yield on the 10-year Treasury eased to 4.48% from 4.51% late Friday. It fell after a survey by the Federal Reserve Bank of New York found that consumers' expectations for coming inflation eased a bit in May. That provides some relief for the Fed, which has been keeping its main interest rate steady as it waits to see how much Trump's tariffs will raise inflation and how much they will hurt the economy. A persistent increase in expectations for inflation among U.S. households could drive behavior that creates a vicious cycle that only worsens inflation. Economists expect a report coming on Wednesday to show inflation across the country accelerated last month to 2.5% from 2.3%. Choe writes for the Associated Press.
